# A Study to Evaluate the Safety and Immunogenicity of Ad5-nCoV and Ad5-nCoV-IH in CoronaVac Immunized Children and Adolescents

> **NCT05169008** · PHASE3 · TERMINATED · sponsor: **CanSino Biologics Inc.** · enrollment: 91 (actual)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
- **BIOLOGICAL:** Recombinant COVID-19 vaccine (adenovirus type 5 vector) for Inhalation (Ad5-nCoV-IH)

## Key facts

- **NCT ID:** NCT05169008
- **Lead sponsor:** CanSino Biologics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-02-25
- **Primary completion:** 2023-01-13
- **Final completion:** 2023-01-13
- **Target enrollment:** 91 (ACTUAL)
- **Why stopped:** Difficulty recruiting subjects, so the study was terminated.
- **Last updated:** 2023-06-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05169008

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05169008, "A Study to Evaluate the Safety and Immunogenicity of Ad5-nCoV and Ad5-nCoV-IH in CoronaVac Immunized Children and Adolescents". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05169008. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*